Anthropic's Claude Science bundles the lab tools scientists usually stitch together into one AI powered workspace. The company is also using it to chase drugs for rare and neglected diseases.
Anthropic shipped Claude Science on June 30, 2026 as a specialized AI workspace aimed at working biologists and drug researchers, not general office users anthropic news. The product bundles tools that scientists typically stitch together themselves: a biomedical literature database (PubMed), a notebook coding environment (Jupyter), the R statistical programming language, and direct access to a high-performance computing cluster over a secure shell terminal (SSH) anthropic news. What the company says distinguishes Claude Science from a general chatbot is native rendering of 3D protein structures, genome browser tracks, and chemical structures, along with the ability to produce figures and manuscript text alongside the code that generated them anthropic news. Scientists can annotate a specific figure or paragraph and the agent revises just that piece rather than rewriting the whole document anthropic news.
The version Anthropic is selling to customers claims the model can carry out meaningful work from concise high-level instructions autonomously and produce auditable artifacts that document the steps it took, rather than just returning a finished answer anthropic news. That is a vendor capability claim, not an independent benchmark. Anthropic has previously evaluated Claude's bioinformatics research chops through BioMysteryBench, but that benchmark is the company's own internal evaluation anthropic research. Independent user validation of Claude Science is essentially zero one day in, since the product only became available to paid Claude subscribers on launch day the-decoder.
The more telling move is that Anthropic is putting its own rare-disease drug research on the same tool it is shipping. The company says it will use Claude Science for research into drugs for rare and neglected diseases, alongside making it available to all paid Claude subscribers at launch anthropic news. That is the difference between a product announcement and a self-applied bet: the same workbench that has to convince biologists it can do real lab work is also the workbench Anthropic is trusting with its own pipeline indianexpress. Whether Claude Science actually surfaces useful rare-disease leads, or falls short on the lab work it is marketed for, is the question worth watching as users start publishing their own results the-decoder.